All patients
Age < 65y (younger) Age > 65y Gender, female Gender, male PDL1 (CPS < 1) PDL1 (CPS >1) Risk favorable (IMDC) Risk favorable (MSKCC) Risk intermediate (IMDC) Risk intermediate (MSKCC) Risk poor (IMDC) Risk poor (MSKCC)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
renal cell cancer (RCC), mTOR inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 025, 2015 0.73 [0.57; 0.93]
KEYNOTE-581/CLEAR (mtor), 2021 1.15 [0.88; 1.50]
0.91 [0.59 ; 1.43 ] CheckMate 025, 2015, KEYNOTE-581/CLEAR (mtor), 2021 2 83% 1,535 moderate not evaluable progression or deaths (PFS)detailed results CheckMate 025, 2015 0.88 [0.75; 1.03]
KEYNOTE-581/CLEAR (mtor), 2021 0.65 [0.53; 0.80]
0.76 [0.57 ; 1.02 ] CheckMate 025, 2015, KEYNOTE-581/CLEAR (mtor), 2021 2 81% 1,535 moderate not evaluable objective responses (ORR)detailed results CheckMate 025, 2015 5.98 [3.68; 9.72]
KEYNOTE-581/CLEAR (mtor), 2021 1.48 [1.26; 1.74]
2.92 [0.74 ; 11.46 ] CheckMate 025, 2015, KEYNOTE-581/CLEAR (mtor), 2021 2 97% 1,535 moderate not evaluable AE (any grade)detailed results KEYNOTE-581/CLEAR (mtor), 2021 5.28 [0.61; 45.46]
5.28 [0.61 ; 45.46 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.53 [1.09; 2.14]
1.53 [1.09 ; 2.14 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.98 [0.94; 4.14]
1.98 [0.94 ; 4.14 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-581/CLEAR (mtor), 2021 2.20 [1.50; 3.23]
2.20 [1.50 ; 3.23 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable TRAE (any grade)detailed results CheckMate 025, 2015 0.50 [0.34; 0.74]
0.50 [0.34 ; 0.74 ] CheckMate 025, 2015 1 0% 803 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.40 [0.29; 0.55]
0.40 [0.29 ; 0.55 ] CheckMate 025, 2015 1 0% 803 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 025, 2015 0.24 [0.01; 5.42]
0.24 [0.01 ; 5.42 ] CheckMate 025, 2015 1 0% 803 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 025, 2015 0.55 [0.34; 0.88]
0.55 [0.34 ; 0.88 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.21 [0.09; 0.48]
0.21 [0.09 ; 0.48 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.98 [0.02; 49.40]
0.98 [0.02 ; 49.40 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.49 [0.09; 2.67]
0.49 [0.09 ; 2.67 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.98 [0.28; 3.40]
0.98 [0.28 ; 3.40 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.98 [0.02; 49.40]
0.98 [0.02 ; 49.40 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 025, 2015 1.47 [0.24; 8.85]
1.47 [0.24 ; 8.85 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Epistaxis TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.98 [0.02; 49.40]
0.98 [0.02 ; 49.40 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.89 [0.37; 2.11]
0.89 [0.37 ; 2.11 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.04 [0.00; 0.67]
0.04 [0.00 ; 0.67 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.32 [0.03; 3.13]
0.32 [0.03 ; 3.13 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.24 [0.01; 5.42]
0.24 [0.01 ; 5.42 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.53 [0.19; 1.44]
0.53 [0.19 ; 1.44 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.98 [0.02; 49.40]
0.98 [0.02 ; 49.40 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.65 [0.11; 3.91]
0.65 [0.11 ; 3.91 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 025, 2015 0.03 [0.00; 0.46]
0.03 [0.00 ; 0.46 ] CheckMate 025, 2015 1 0% 803 NA not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 4.84 [0.56; 41.67]
4.84 [0.56 ; 41.67 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.92 [0.06; 57.36]
1.92 [0.06 ; 57.36 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 4.43 [1.66; 11.83]
4.43 [1.66 ; 11.83 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 2.34 [1.31; 4.15]
2.34 [1.31 ; 4.15 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Dysgeusia AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 0.48 [0.02; 14.30]
0.48 [0.02 ; 14.30 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Dysphonia AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 3.85 [0.17; 85.62]
3.85 [0.17 ; 85.62 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.78 [0.93; 3.41]
1.78 [0.93 ; 3.41 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Hypertension AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.25 [0.87; 1.81]
1.25 [0.87 ; 1.81 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 3.85 [0.17; 85.62]
3.85 [0.17 ; 85.62 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 4.40 [0.94; 20.50]
4.40 [0.94 ; 20.50 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 0.73 [0.32; 1.69]
0.73 [0.32 ; 1.69 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Proteinuria AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 2.94 [1.41; 6.12]
2.94 [1.41 ; 6.12 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 0.48 [0.04; 5.29]
0.48 [0.04 ; 5.29 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Stomatitis AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 3.14 [1.32; 7.46]
3.14 [1.32 ; 7.46 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.94 [0.66; 5.74]
1.94 [0.66 ; 5.74 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Weight decreased AE (grade 3-4)detailed results Out of scale KEYNOTE-581/CLEAR (mtor), 2021 26.79 [3.61; 198.57]
26.79 [3.61 ; 198.57 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-03 05:41 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 10,93,79,178,152,80
- treatments: 711,507,1040,1434
